# SkyAI, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/SkyAI, Inc.). ## Overview SkyAI, Inc. is a U.S.-based medical device company focused on syringe products and related drug-delivery systems. Its business includes the marketing and distribution of disposable and prefillable syringes, with operations tied to both domestic and international healthcare markets. ## Products & services • Disposable syringe products • Prefillable syringe products • Securgard syringe product line • Sologard syringe product line • Related drug-delivery systems • Medical device distribution services - **Disposable syringes** (45%) — Single-use syringe products marketed for clinical and healthcare use. - **Prefillable syringes** (20%) — Syringe platforms designed for drug-delivery and pharmaceutical applications. - **Securgard and Sologard products** (20%) — Named syringe product lines used in the company's commercial offering. - **Distribution and inventory sales** (15%) — Sales of existing inventory and third-party medical products through distribution channels. - Disposable syringe products - Prefillable syringe products - Securgard syringe product line - Sologard syringe product line - Related drug-delivery systems - Medical device distribution services ## Customers The company sells to healthcare companies, distributors, hospitals, clinics, healthcare providers, and medical supply organizations. It also targets U.S. and foreign governments for syringe and related medical product procurement. Customer demand is driven by the need for reliable, compliant, commercially available syringe supply. - **Healthcare distributors** (primary) — Buy syringe inventory and product lines for onward distribution into healthcare channels. - **Hospitals and clinics** (primary) — Purchase syringes for direct clinical use and routine patient care. - **Healthcare companies** (primary) — Source syringe products and drug-delivery systems for commercial supply arrangements. - **Government buyers** (secondary) — Procure syringe products for public health, medical stockpiles, or institutional use. - **Medical supply organizations** (secondary) — Buy and distribute syringe products to healthcare providers and institutions. - Healthcare companies buying syringe supply for resale or use - Distributors seeking commercial quantities and recurring supply - Hospitals and clinics purchasing for clinical administration - Medical supply organizations serving healthcare end markets - U.S. and foreign governments procuring medical devices - Healthcare groups needing safety and prefillable syringe formats ## Geography The company is headquartered in the United States and maintains a corporate office in Melville, New York. It also operates through a Hungarian manufacturing facility and markets products in both domestic and international markets, including Europe. Geography matters because manufacturing capacity, regulatory approvals, and customer access are all tied to where products are produced and sold. - **United States** (50%) — Corporate base and primary domestic market - **Europe** (50%) — International markets and Hungarian operations - United States is the corporate base and a core sales market - Melville, New York is the company office location - Hungary is an important manufacturing and testing location - Products are marketed in domestic and international markets - European customers are relevant to distribution and order fulfillment - Regulatory compliance differs across U.S. and foreign markets ## Strategy The company is focused on commercializing and distributing syringe products while building supply relationships with healthcare customers and distributors. It is also using its Hungarian facility and inventory base to support commercial quantities and order fulfillment. Beyond medical devices, it has added a digital asset treasury strategy centered on SOL and is exploring additional investments and acquisitions. - **Commercialize syringe products** (short-term) — Revenue depends on converting product development and inventory into repeat customer orders. - **Preserve and expand manufacturing capacity** (short-term) — Commercial supply requires reliable production and delivery capability. - **Broaden distribution platform** (medium-term) — Representing third-party products can extend the customer base and reduce reliance on a narrow product set. - **Build treasury and capital flexibility** (medium-term) — The SOL treasury is intended to provide an additional reserve and potential funding source. - Expand syringe commercialization through distribution and supply agreements - Use Hungarian capacity to support manufacturing and order fulfillment - Sell existing inventory to convert product development into revenue - Represent complementary third-party medical products over time - Maintain a SOL treasury strategy as a separate capital allocation priority - Explore acquisitions and investments that could broaden the platform ## Risks The business depends on successful commercialization of syringe products, customer acceptance, and uninterrupted manufacturing or distribution capacity. It also faces regulatory, inventory, and execution risk because medical devices require quality compliance and demand can be lumpy across customers and geographies. The added digital asset treasury strategy introduces market, custody, and valuation risk that is separate from the core medical device business. - **Commercialization and demand risk** [high] — Revenue depends on converting syringe products into repeat orders from healthcare buyers and distributors. - **Regulatory and quality compliance risk** [high] — Medical devices must meet FDA and comparable international standards, and failures can block sales or trigger remediation. - **Inventory reserve and obsolescence risk** [medium] — The company carries syringe inventory, and slow sales can require write-downs or reserves. - **Manufacturing concentration risk** [medium] — A key facility in Hungary supports production and testing, so disruptions could affect supply. - **Digital asset market risk** [high] — SOL holdings and staking revenue expose the company to price volatility, custody, and transaction risk. - **Advisor and related-party governance risk** [low] — Non-arm's-length arrangements can produce less favorable commercial terms. - Commercial adoption risk if syringe orders do not scale - Regulatory and quality compliance risk across medical device markets - Inventory obsolescence and reserve risk from slow-moving stock - Manufacturing and supply chain disruption risk in Hungary - Digital asset volatility and custody risk from SOL holdings - Related-party or advisor arrangement risk if terms are not arm's length ## Accounting Revenue recognition is important because the company has only recently begun generating product revenue and also records staking revenue from digital assets. Inventory valuation, reserves, and fixed-asset impairment are key judgment areas because the business has carried syringe inventory and has recognized write-downs on long-lived assets. Fair value accounting for warrants, derivatives, and digital assets can create large period-to-period swings in reported results. - **Revenue recognition for syringe sales** — Reported sales may be uneven as orders ramp - **Inventory valuation and reserves** — Gross margin and asset values can be reduced - **Impairment of long-lived assets** — Non-cash charges can materially affect earnings - **Fair value of warrants and derivatives** — Large gains or losses may not reflect core operations - **Digital asset accounting** — Balance sheet and income statement volatility - Product revenue timing affects reported sales as orders begin to convert - Inventory reserves can reduce gross margin when stock is excess or slow-moving - Long-lived asset impairment can create large non-cash charges - Warrant and derivative fair value changes can swing earnings materially - Digital asset valuation and staking revenue affect reported results - Foreign currency effects matter because operations span the U.S. and Hungary --- *Last updated: 2026-06-16T23:10:09.093953+00:00*